

## **MDL - RSV/Influenza/Covid-19 (RIC) Test**

### **Healthcare Provider Information Sheet**

#### **Test Information**

The MDL RSV/Influenza/SARS-CoV-2 (RIC) assay is a multiplexed reverse transcription polymerase chain reaction (RT-PCR) test that is validated for use with all upper respiratory samples in people of all ages. The test targets multiple regions of the SARS-CoV-2 organism (spike and nucleocapsid) and has 100% homology for all known strains of SARS-CoV-2. Additionally, the test targets a shared region of Respiratory syncytial virus (RSV) A and B as well as a shared region of Influenza A and B. If a patient sample has detectable RSV A/B or Influenza A/B, the result will state positive for RSV or positive for Influenza without calling a subtype, as we cannot distinguish between the subtypes by this assay. This assay will not detect Influenza C.

#### **Sample Collection and Submission**

Samples should be collected by trained healthcare providers using appropriate infection control precautions. Guidance should be sought by viewing the CDC website for sample collection methods. MDL sample collection kits should be used for all samples to be submitted to MDL. To order more collection kits, visit our website: [wichita.edu/mdl](http://wichita.edu/mdl).

#### **Test Interpretation**

All three targets are listed separately on the report with a positive or negative result. It is possible to have a co-infection with multiple viruses detectable in a sample. The limit of detection of the assay is 200 copies/ $\mu$ L. If virus is present in the sample, but the viral load is below this threshold, the test will not detect the virus and the result will be negative. If a sample tests positive for a viral target, this means there was detectable RNA (>200 copies/ $\mu$ L) from that virus in the sample. The likelihood of a false positive is very low; however, false negative and false positive results are always possible with any lab test. Patients suspected of infection with SARS-CoV-2 or any other illness should be evaluated and treated based on symptoms and clinical evaluations, not just the results of this assay.